CD4 and neoplasm: Consistent with these results, we and others have shown that tumor-specific CD4+ T-cells are sometimes a required component of curative AIT in syngeneic mouse tumor models, and that co-transfer of IFNγ-producing anti-tumor CD4+ and CD8+ T cells can markedly accelerate tumor rejection [8–11].